Intel Co. (INTC) Shares Sold by Ramsay Stattman Vela & Price Inc.

Ramsay Stattman Vela & Price Inc. decreased its stake in shares of Intel Co. (NASDAQ:INTC) by 4.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 28,276 shares of the chip maker’s stock after selling 1,470 shares during the period. Ramsay Stattman Vela & Price Inc.’s holdings in Intel were worth $1,473,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of INTC. Goodman Financial Corp acquired a new position in Intel during the fourth quarter worth approximately $102,000. Virtue Capital Management LLC acquired a new position in Intel during the fourth quarter worth approximately $109,000. Delphi Private Advisors LLC grew its stake in Intel by 286.1% during the fourth quarter. Delphi Private Advisors LLC now owns 2,911 shares of the chip maker’s stock worth $134,000 after buying an additional 2,157 shares during the period. First Dallas Securities Inc. purchased a new stake in Intel during the fourth quarter worth approximately $144,000. Finally, Financial Gravity Companies Inc. purchased a new stake in Intel during the fourth quarter worth approximately $157,000. 66.85% of the stock is owned by hedge funds and other institutional investors.

Get Intel alerts:

INTC has been the subject of several research reports. Wells Fargo & Co reiterated an “outperform” rating and set a $65.00 price objective on shares of Intel in a research note on Friday, April 27th. Bank of America reiterated a “buy” rating and set a $65.00 price objective on shares of Intel in a research note on Wednesday, April 18th. DZ Bank reiterated a “hold” rating and set a $53.00 price objective on shares of Intel in a research note on Wednesday, March 28th. Vetr downgraded shares of Intel from a “strong-buy” rating to a “buy” rating and set a $54.41 price objective for the company. in a research note on Friday, March 30th. Finally, Macquarie reiterated a “buy” rating and set a $64.00 price objective on shares of Intel in a research note on Friday, May 18th. Three equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and twenty-nine have issued a buy rating to the company. Intel presently has a consensus rating of “Buy” and an average price target of $55.78.

In other Intel news, EVP Navin Shenoy sold 498 shares of the stock in a transaction on Tuesday, April 24th. The shares were sold at an average price of $52.31, for a total transaction of $26,050.38. Following the sale, the executive vice president now directly owns 30,502 shares of the company’s stock, valued at $1,595,559.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Brian M. Krzanich sold 6,746 shares of the stock in a transaction on Thursday, April 26th. The stock was sold at an average price of $52.52, for a total transaction of $354,299.92. Following the sale, the chief executive officer now directly owns 264,084 shares in the company, valued at $13,869,691.68. The disclosure for this sale can be found here. Insiders have sold 13,192 shares of company stock worth $693,559 over the last three months. 0.03% of the stock is owned by corporate insiders.

Shares of NASDAQ:INTC opened at $52.50 on Friday. The firm has a market cap of $244.16 billion, a price-to-earnings ratio of 15.17, a price-to-earnings-growth ratio of 1.59 and a beta of 0.95. Intel Co. has a 1-year low of $33.23 and a 1-year high of $57.60. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.23 and a current ratio of 1.58.

Intel (NASDAQ:INTC) last issued its earnings results on Thursday, April 26th. The chip maker reported $0.87 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.72 by $0.15. The company had revenue of $16.10 billion for the quarter, compared to analysts’ expectations of $15.08 billion. Intel had a net margin of 17.32% and a return on equity of 25.41%. The firm’s revenue was up 8.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.66 earnings per share. equities research analysts anticipate that Intel Co. will post 3.99 EPS for the current year.

About Intel

Intel Corporation designs, manufactures, and sells computer, networking, data storage, and communication platforms worldwide. The company operates through Client Computing Group, Data Center Group, Internet of Things Group, Non-Volatile Memory Solutions Group, Programmable Solutions Group, and All Other segments.

Want to see what other hedge funds are holding INTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intel Co. (NASDAQ:INTC).

Clean Energy Fuels Corp Stock Jumped 10% Today -- Here's Why

What happened

Shares of transportation-focused natural gas seller�Clean Energy Fuels Corp�(NASDAQ:CLNE) finished trading up 9.8% on June 22, 2018, closing out a great week that saw the company's stock price gain 19.2%. Today's big jump was most likely a product of the big news out of OPEC, which pushed oil prices sharply higher. Brent, an important global benchmark for crude oil futures, rose almost 3.6% today, while West Texas Intermediate, the major U.S. market price benchmark, increased over 5.7%. This marked the highest market price for crude oil futures in almost a month, when word of OPEC's initial plan first came out and oil prices started falling.�

The irony about today's price surge is that the catalyst was OPEC's announcement to�increase�oil production. The reasoning is simple: The final agreement, which calls for a ramp up to an additional 1 million barrels of oil per day over the next month -- though it's expected to take some time for producers to ramp up that much -- was well-received because many were fearing OPEC would raise its target even higher, potentially leaving the market awash in a crude oversupply.�

Image source: Getty Images.

In other words, the market got something it absolutely loves: a measure of predictability and certainty. OPEC's move actually looks like it could forestall even higher prices later this year since projections show current output won't meet demand later in the year. This is a result of multiple years of weak oilfield development during the oil and gas downturn that started in late 2014.�

So what

This is good news for Clean Energy Fuels because more certainty around relatively higher oil prices means that commercial vehicle fleet operators, seeing higher diesel and gasoline prices as a long-term concern, will continue to explore and to switch to natural gas-powered vehicles. These cost significantly less to refuel.�

Two recent announcements bear this out.�On June 20, the company announced it "...facilitated the filing of grant applications for 168 heavy-duty trucks equipped with the latest near zero engine technology and powered by Clean Energy's Redeem renewable natural gas." For some context, 168 heavy-duty trucks could easily consume 3.4 million-gallon equivalents of natural gas per year. On June 22, the company announced the opening of a compressed natural gas station in Kansas that would provide over 1.2 million-gallon equivalents of natural gas to 170 transit buses and refuse vehicles serving the Johnson County area.�

Now what

On May 10, Clean Energy Fuels reported first-quarter earnings and announced that oil and gas giant�Total SA�was taking a 25% stake in the company. Since then, its share price has increased 77%. Going back to the low point on March 1, the company's stock price has surged 157%. Yet even after these big gains, Clean Energy still looks like a great investment.�

The diesel market in North America is more than 50 billion gallons per year, and last year it sold less than 400 million gallons of natural gas -- meaning there's substantial opportunity to grow from here. With the company's market capitalization of $529 million at the closing price today, its stock's recent run-up hasn't pushed its value into extreme premium territory.�

Furthermore, it's unlikely that alternatives like EVs and hydrogen will be road ready for heavy transit for many years to come, while natural gas supplied by Clean Energy is cheaper and cleaner -- and available -- today.�

Jounce Therapeutics Inc (JNCE) Insider Buys $14,896.00 in Stock

Jounce Therapeutics Inc (NASDAQ:JNCE) insider Hugh M. Cole acquired 1,900 shares of the business’s stock in a transaction on Friday, June 15th. The shares were bought at an average cost of $7.84 per share, with a total value of $14,896.00. Following the completion of the acquisition, the insider now owns 1,900 shares of the company’s stock, valued at approximately $14,896. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of NASDAQ:JNCE opened at $7.93 on Tuesday. Jounce Therapeutics Inc has a twelve month low of $6.92 and a twelve month high of $29.25. The firm has a market capitalization of $257.27 million, a PE ratio of -13.91 and a beta of 5.55.

Get Jounce Therapeutics alerts:

Jounce Therapeutics (NASDAQ:JNCE) last announced its earnings results on Wednesday, May 9th. The company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.09). Jounce Therapeutics had a negative net margin of 47.73% and a negative return on equity of 19.90%. The business had revenue of $11.20 million during the quarter, compared to analyst estimates of $13.33 million. sell-side analysts predict that Jounce Therapeutics Inc will post -1.54 EPS for the current year.

A number of analysts have recently weighed in on the company. Cowen lowered Jounce Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 5th. Robert W. Baird lowered their target price on Jounce Therapeutics from $35.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, June 4th. JPMorgan Chase & Co. lowered Jounce Therapeutics from an “overweight” rating to a “neutral” rating and set a $12.00 target price for the company. in a research note on Monday, June 4th. Wells Fargo & Co lowered their target price on Jounce Therapeutics to $10.00 and set a “market perform” rating for the company in a research note on Thursday, May 31st. Finally, TheStreet lowered Jounce Therapeutics from a “c-” rating to a “d+” rating in a research note on Tuesday, May 22nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $15.00.

Several large investors have recently made changes to their positions in JNCE. SG Americas Securities LLC acquired a new stake in shares of Jounce Therapeutics in the fourth quarter valued at $294,000. Swiss National Bank increased its position in Jounce Therapeutics by 84.3% in the fourth quarter. Swiss National Bank now owns 24,700 shares of the company’s stock worth $315,000 after purchasing an additional 11,300 shares during the period. Wells Fargo & Company MN increased its position in Jounce Therapeutics by 101.7% in the fourth quarter. Wells Fargo & Company MN now owns 41,908 shares of the company’s stock worth $534,000 after purchasing an additional 21,127 shares during the period. Rhumbline Advisers acquired a new stake in Jounce Therapeutics in the fourth quarter worth about $134,000. Finally, Bank of New York Mellon Corp increased its position in Jounce Therapeutics by 10.8% in the fourth quarter. Bank of New York Mellon Corp now owns 45,889 shares of the company’s stock worth $585,000 after purchasing an additional 4,467 shares during the period. Institutional investors own 91.55% of the company’s stock.

About Jounce Therapeutics

Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.

Traders Buy Shares of iShares Barclays 7-10 Year Trasry Bnd Fd (IEF) on Weakness

Traders purchased shares of iShares Barclays 7-10 Year Trasry Bnd Fd (NASDAQ:IEF) on weakness during trading on Friday. $118.85 million flowed into the stock on the tick-up and $66.32 million flowed out of the stock on the tick-down, for a money net flow of $52.53 million into the stock. Of all stocks tracked, iShares Barclays 7-10 Year Trasry Bnd Fd had the 17th highest net in-flow for the day. iShares Barclays 7-10 Year Trasry Bnd Fd traded down ($0.14) for the day and closed at $101.71

The firm also recently disclosed a monthly dividend, which was paid on Thursday, June 7th. Shareholders of record on Monday, June 4th were paid a $0.2023 dividend. This represents a $2.43 dividend on an annualized basis and a yield of 2.39%. The ex-dividend date was Friday, June 1st. This is an increase from iShares Barclays 7-10 Year Trasry Bnd Fd’s previous monthly dividend of $0.19.

Large investors have recently made changes to their positions in the business. UBS Group AG grew its stake in shares of iShares Barclays 7-10 Year Trasry Bnd Fd by 88.2% during the 1st quarter. UBS Group AG now owns 3,344,460 shares of the exchange traded fund’s stock worth $345,115,000 after acquiring an additional 1,567,704 shares during the period. Envestnet Asset Management Inc. grew its stake in shares of iShares Barclays 7-10 Year Trasry Bnd Fd by 42.4% during the 4th quarter. Envestnet Asset Management Inc. now owns 3,502,953 shares of the exchange traded fund’s stock worth $369,808,000 after acquiring an additional 1,043,431 shares during the period. BlackRock Inc. grew its stake in shares of iShares Barclays 7-10 Year Trasry Bnd Fd by 55.2% during the 4th quarter. BlackRock Inc. now owns 1,551,103 shares of the exchange traded fund’s stock worth $163,750,000 after acquiring an additional 551,456 shares during the period. Brouwer & Janachowski LLC bought a new position in shares of iShares Barclays 7-10 Year Trasry Bnd Fd during the 1st quarter worth $55,066,000. Finally, Mizuho Trust & Banking Co. Ltd. bought a new position in shares of iShares Barclays 7-10 Year Trasry Bnd Fd during the 1st quarter worth $54,691,000.

About iShares Barclays 7-10 Year Trasry Bnd Fd

iShares 7-10 Year Treasury Bond ETF (the Fund) is an is an exchange-traded fund. The Fund seeks to track the investment results of an index composed of the United States Treasury bonds with remaining maturities between seven and ten years. The Fund seeks to track the investment results of the Barclays U.S.